Aim: The aim of this study was to determine if nevus-associated melanoma differs in characteristics and prognosis from de novo melanoma.
Patients And Methods: The study included 118 melanoma patients. Clinical findings were retrospectively evaluated. For histopathological parameters, HE sections were reexamined. The differentiation between de novo and nevus-associated melanoma was based on the histopathological evidence of a precursor nevus. In addition, all analyses were repeated in all cases in which nevus-associated melanoma was defined based on patient anamnesis.
Results: Among all patients, 28 (23.7%) had nevus-associated melanoma. Nevus-associated melanoma was most commonly located on the extremities (50%), followed by the trunk (25%), whereas de novo melanoma was most commonly located in the head and neck region (32.2%), followed by the acral region (31.1%). Other clinical findings and histopathological parameters did not differ significantly between the two groups (p > 0.05). The findings remained consistent following the repeated analysis of all cases in which nevus-associated melanoma was defined based on patient anamnesis.
Conclusions: Nevus-associated melanoma was most commonly located on the extremities and the trunk, whereas de novo melanoma was most commonly located in the head and neck and the acral region. Furthermore, nevus-associated melanoma was similar to de novo melanoma in terms of prognosis and other disease characteristics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816428 | PMC |
http://dx.doi.org/10.1159/000375490 | DOI Listing |
J Am Acad Dermatol
November 2024
Department of Oncology, Cancer Center, The First Hospital of Jilin University, Changchun, China. Electronic address:
Background: It is unknown whether acral melanomas (AMs) associated with pre-existing nevi have similar risk to other AMs.
Objective: To compare risk of recurrence and death between AMs associated with pre-existing nevi and de novo AMs.
Methods: We conducted a multicenter retrospective cohort study involving patients diagnosed with AMs between February 2011 and November 2022.
J Immunother Cancer
November 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ/11 mutations. Tebentafusp was recently approved for UM based on improved overall survival in a phase 3 study. We hypothesized that tebentafusp may be active in BN-associated melanoma.
View Article and Find Full Text PDFJ Cutan Pathol
October 2024
Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA.
Hum Pathol
June 2024
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China. Electronic address:
This study investigated the clinicopathological, immunohistochemical, and molecular features of primary leptomeningeal melanocytic neoplasms (LMNs). Twelve LMN cases were retrospectively reviewed. We performed Fluorescence in-situ hybridization (including a 4-probe FISH assay with CDKN2A and MYC assay) and Next-Generation sequencing analyses on available cases.
View Article and Find Full Text PDFActa Derm Venereol
April 2024
Skin Cancer Center, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Nevus-associated lentigo maligna and lentigo maligna melanoma (NALMM) are rarely described in the literature and are considered an incidental finding. This study aimed to evaluate the frequency of NALMM and its clinicopathological features. A total of 201 histopathology reports were reviewed and among them 20% of the samples corresponded to NALMM, with females overrepresented in this group (p = 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!